Table 1.

Graft and patient survival after kidney transplantation, by HCV statusa

StudyNo. of Kidney Transplant PatientsbDuration of Follow-upGraft/Patient Survival
Studies with survival worse in HCV+ than in HCV− transplant recipients
    Bruchfeld et al., 2004 (29)545, 26 kidney-pancreas transplant recipients; 51 HCV+5 yrHCV+ patients had shorter graft and patient survival
RR for graft loss 1.96 in HCV+ patients
    Mathurin et al., 1999 (6)834, 216 HCV+10 yr10-yr survival 65% for HCV+ patients; survival significantly lower than in HBV+ and HCV− patients
    Mahmoud et al., 2004 (30)133; 87 HCV+9 yrHCV+ patients with high ALT levels at increased risk for graft failure (OR 3.0) or death (OR 3.7)
Five HCV+ and no HCV− recipients died of liver disease
    Periera et al., 1995 (31)103; 23 HCV+45 moRR for graft loss 1.3 (95% CI 0.6 to 2.6)
RR for posttransplantation death 3.3 (95% CI 1.4 to 7.9)
RR for death from sepsis 9.9 (95% CI 2.6 to 38.3)
    Stehman-Breen et al., 1997 (32)137 HCV+ kidney-pancreas transplant recipients; 12 HCV+HCV+: 30.4 mo; HCV−: 31.7 moAbsolute risk reduction for graft failure 5.1 (95% CI 1.7 to 15.4)
Studies with survival not different in HCV+ versus HCV− transplant recipients
    Stempel et al., 1993 (33)596; 64 HCV+5 yrNo differences in graft survival, overall mortality, or mortality as a result of liver disease or sepsis related to HCV status
    Roth et al., 1994 (34)641; 169 HCV+65.7 moHCV status had no effect on graft and patient survival
HCV+ independent predictor of liver disease
HCV+ patients at greater risk for infectious events (P = 0.03) and rejection episodes (P = 0.002)
  • a ALT, alanine aminotransferase; CI, confidence interval; HBV, hepatitis B virus; HCV, hepatitis C virus; OR, odds ratio; RR, relative risk.

  • b Limited to studies of ≥100 kidney transplant recipients.